Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Conditions
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer
Trial Timeline
Nov 1, 2010 → Apr 1, 2019
NCT ID
NCT01935492About Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine is a phase 3 stage product being developed by Roche for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast. The current trial status is completed. This product is registered under clinical trial identifier NCT01935492. Target conditions include Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01935492 | Phase 3 | Completed |
Competing Products
20 competing products in Human Epidermal Growth Factor 2 Negative Carcinoma of Breast